Top

Published in:

Open Access 01-10-2009 | Original paper

Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccination

Authors: Richard A. Moore, Gina Ogilvie, Daniel Fornika, Veronika Moravan, Marc Brisson, Mahsa Amirabbasi-Beik, Anita Kollar, Thomas Burgess, Ray Hsu, Laura Towers, Jane Lo, Jasenka Matisic, Angela Brooks-Wilson

Published in: Cancer Causes & Control | Issue 8/2009

Abstract

Background

Human papilloma virus (HPV) prevalence studies performed in different regions and population groups across Canada would inform public health decisions regarding implementation of anti-HPV vaccines.

Methods

A total of 8,700 liquid-based specimens from 8,660 women aged 13–86 from throughout British Columbia were collected. DNA was isolated from 4,980 of these samples and assessed for HPV prevalence and type distribution. HPV was detected by PCR analysis using tagged GP5+/6+ consensus primers to amplify the L1 region of HPV; typing was done by bi-directional sequencing of PCR products.

Results

Overall HPV prevalence was 16.8% (age adjusted 15.5%). Prevalence of high-risk HPV was 13.9, and 10.7% of samples contained HPV16. HPV prevalence was highest in the youngest group of women (<20 years). One-third of HPV positive samples contained more than one HPV type. Percentages of low-grade (LGIL) and high-grade intraepithelial lesions (HGIL) containing high-risk HPV are 52.3 and 79.4%, respectively.

Conclusions

Overall HPV prevalence in this study is within the range of estimates from other studies. The prevalence of HPV16 is higher than what is found in other Canadian and international studies. HPV16 and HPV18 compose a majority of the high-risk virus in this study. Use of current HPV vaccines could considerably reduce HPV-related conditions including cervical cancer and procedures such as colposcopy.

Available only for authorised users

Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F PubMedCrossRef

Munoz N, Mendez F, Posso H et al (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190:2077–2087. doi:10.1086/425907 PubMedCrossRef

Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765. doi:10.1016/S0140-6736(04)17398-4 PubMedCrossRef

Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255. doi:10.1016/S0140-6736(06)68439-0 PubMedCrossRef

Koutsky LA, Ault KA, Wheeler CM et al (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651. doi:10.1056/NEJMoa020586 PubMedCrossRef

Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278. doi:10.1016/S1470-2045(05)70101-7 PubMedCrossRef

Shi L, Sings HL, Bryan JT et al (2007) GARDASIL: prophylactic human papillomavirus vaccine development–from bench top to bed-side. Clin Pharmacol Ther 81:259–264. doi:10.1038/sj.clpt.6100055 PubMedCrossRef

SurePath (2005) British Columbia Cervical Cancer Screening Program Feasibility Study: SurePath TM Liquid-Based Cytology: BC Cancer Agency

de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ (1995) The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76(Pt 4):1057–1062. doi:10.1099/0022-1317-76-4-1057 PubMedCrossRef

10.

Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K (2004) A large case–control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 189:1829–1832. doi:10.1086/382896 PubMedCrossRef

11.

Young TK, McNicol P, Beauvais J (1997) Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. Sex Transm Dis 24:293–298. doi:10.1097/00007435-199705000-00011 PubMed

12.

CCSP (2004) British Columbia Cervical Cancer Screening Program 2004 annual report: BC Cancer Agency

13.

Dunne EF, Unger ER, Sternberg M et al (2007) Prevalence of HPV infection among females in the United States. Jama 297:813–819. doi:10.1001/jama.297.8.813 PubMedCrossRef

14.

Brown DR, Rawlings K, Handy V et al (1996) Human papillomavirus detection by hybrid capture in paired cervicovaginal lavage and cervical biopsy specimens. J Med Virol 48:210–214. doi:10.1002/(SICI)1096-9071(199602)48:2<210::AID-JMV15>3.0.CO;2-I PubMedCrossRef

15.

Sellors JW, Lorincz AT, Mahony JB et al (2000) Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Cmaj 163:513–518PubMed

16.

Ogilvie GS, Patrick DM, Schulzer M et al (2005) Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 81:207–212. doi:10.1136/sti.2004.011858 PubMedCrossRef

17.

Pham TH, Nguyen TH, Herrero R et al (2003) Human papillomavirus infection among women in South and North Vietnam. Int J Cancer 104:213–220. doi:10.1002/ijc.10936 PubMedCrossRef

18.

Castellsague X, Menendez C, Loscertales MP et al (2001) Human papillomavirus genotypes in rural Mozambique. Lancet 358:1429–1430. doi:10.1016/S0140-6736(01)06523-0 PubMedCrossRef

19.

Sellors JW, Mahony JB, Kaczorowski J et al (2000) Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) group. Cmaj 163:503–508PubMed

20.

Coupé VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ (2008) Age-dependent prevalence of 14 high-risk HPV types in The Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98(3):646–651. doi:10.1038/sj.bjc.6604162 PubMedCrossRef

21.

Bao YP, Li N, Smith JS, Qiao YL, ACCPAB members (2008) Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 18(1):71–79PubMedCrossRef

22.

Sukvirach S, Smith JS, Tunsakul S et al (2003) Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 187:1246–1256. doi:10.1086/373901 PubMedCrossRef

23.

Thomas JO, Herrero R, Omigbodun AA et al (2004) Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 90:638–645. doi:10.1038/sj.bjc.6601515 PubMedCrossRef

24.

Molano M, van den Brule AJ, Posso H et al (2002) Low grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women. Br J Cancer 87:1417–1421. doi:10.1038/sj.bjc.6600650 PubMedCrossRef

25.

de Sanjose S, Almirall R, Lloveras B et al (2003) Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 30:788–793. doi:10.1097/01.OLQ.0000080177.82204.E0 PubMedCrossRef

26.

Matos E, Loria D, Amestoy GM et al (2003) Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 30:593–599. doi:10.1097/01.OLQ.0000085181.25063.6C PubMedCrossRef

27.

Shin HR, Lee DH, Herrero R et al (2003) Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 103:413–421. doi:10.1002/ijc.10825 PubMedCrossRef

28.

Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991–998. doi:10.1016/S0140-6736(05)67069-9 PubMedCrossRef

29.

Vernon SD, Unger ER, Williams D (2000) Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 38:651–655PubMed

30.

Manhart LE, Holmes KK, Koutsky LA et al (2006) Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 33:502–508. doi:10.1097/01.olq.0000204545.89516.0a PubMedCrossRef

31.

Sellors JW, Karwalajtys TL, Kaczorowski JA et al (2002) Prevalence of infection with carcinogenic human papillomavirus among older women. Cmaj 167:871–873PubMed

32.

Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV (2001) Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol 63:284–292. doi:10.1002/1096-9071(200104)63:4<284::AID-JMV1003>3.0.CO;2-H PubMedCrossRef

33.

Richardson H, Kelsall G, Tellier P et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:485–490PubMed

34.

Chan PK, Cheung TH, Tam AO et al (2006) Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118:243–245. doi:10.1002/ijc.21299 PubMedCrossRef

Title: Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccination
Authors: Richard A. Moore
Gina Ogilvie
Daniel Fornika
Veronika Moravan
Marc Brisson
Mahsa Amirabbasi-Beik
Anita Kollar
Thomas Burgess
Ray Hsu
Laura Towers
Jane Lo
Jasenka Matisic
Angela Brooks-Wilson
Publication date: 01-10-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9365-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2009

Lifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg

Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma

Access to mammography screening in a large urban population: a multi-level analysis

Association of metabolic syndrome with insulin-like growth factors among adults in the US

Ionizing radiation: a risk factor for mesothelioma

Reply to: Dr. Peter Morfeld’s Letter to the Editor (Manuscript Number: CACO2009): “Comment on Lacasse Y, Martin S, Gagne D, Lakhal L (2009) Dose–response meta-analysis of silica and lung cancer. Cancer Causes and Control; [e-pub ahead of print] doi: 10.1007/s10552-009-9296-0”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer